Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
≥98% Purity
Oral and Capsule Research CompoundsSKU: CP-BB500
Oral BPC-157 + TB-500 Blend 1000mcg
≥98% PuritySupplier batch spec; selected lots Janoshik-tested
€722.49In Stock
Only 1 left in stock — order soon
Delivers to EU in 11-14 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Research-grade Oral BPC-157 + TB-500 Blend. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Oral capsules in sealed bottle. For laboratory research use only. Not for human consumption.
Volume PricingApplied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €722.49 | €722.49 | -- |
| 3+ | €686.37 | €2,059.10 | 5% off |
| 5+Most Popular | €650.24 | €3,251.21 | 10% off |
| 10+ | €614.12 | €6,141.17 | 15% off |
1
Total: €722.49
Free shipping on orders over €200
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Purity HPLC
99.3% average HPLC purity, verified by independent third-party testing
Third-Party Tested
Janoshik report published when available
Fast Shipping
24h dispatch, EU-wide shipping from €4.99
Third-Party Tested
Supplier batch specification on every product; independent Janoshik report on selected lots
Last reviewed: 2026-06-05
About Oral BPC-157 + TB-500 Blend 1000mcg
Oral BPC-157 + TB-500 Blend combines 500mcg each of BPC-157 and TB-500 in a single capsule. The combination pairs BPC-157's well-documented gastric acid stability with TB-500's actin-modulating tissue biology, making it useful for researchers studying oral peptide delivery alongside the potential for complementary tissue remodeling mechanisms in GI tissue models.
BPC-157 and TB-500 have been studied independently for overlapping but distinct properties: BPC-157 primarily through nitric oxide pathway modulation and mucosal cytoprotection; TB-500 through actin dynamics, cell migration, and angiogenesis. Both have published preclinical work in tissue remodeling contexts, and there are proposed mechanistic interactions. Whether oral co-administration produces additive, synergistic, or simply independent effects is the kind of question this blend is designed to help researchers address. The format is straightforward -- one capsule for researchers who want to study both peptides as a combined oral intervention.
One practical consideration: BPC-157's gastric acid stability means it survives to reach intestinal tissue, while TB-500's GI survival is less certain. This means the blend may effectively deliver primarily BPC-157 to GI tissue, with TB-500's contribution depending on formulation protection. Research designs using this blend should account for this asymmetry in oral bioavailability between the two components.
Research Applications
Useful for combination research in tissue remodeling models, comparative studies of individual versus combined peptide administration via oral route, and investigation of mechanistic interactions between nitric oxide signaling (BPC-157) and actin cytoskeleton dynamics (TB-500) in GI and tissue-repair model systems.
Specifications
| Parameter | Value |
|---|---|
| Component 1 | BPC-157 500mcg (CAS 137525-51-0) |
| Component 2 | TB-500 500mcg (Thymosin Beta-4 fragment) |
| Total Dose | 1,000mcg combined per capsule |
| Purity | ≥98% (supplier batch spec; 99.3% avg across independently tested lots, each component) |
| Format | Oral capsule, lyophilized fill |
| Capsules per Bottle | 60 |
| Storage | Room temperature or refrigerate for extended stability |
Storage
Store at room temperature in a cool, dry place; refrigerate for longer-term stability. Keep dry and away from heat sources. The capsule fill is lyophilized, providing better stability than reconstituted solutions.
Are BPC-157 and TB-500 synergistic?
Some combination studies suggest additive or enhanced effects when both are administered together, but the mechanistic basis is not fully characterized. BPC-157 primarily modulates the nitric oxide system and mucosal tissue pathways; TB-500 acts through actin cytoskeleton dynamics and cell migration. These pathways are distinct but tissue remodeling involves both cellular motility (TB-500 territory) and vascular support plus mucosal protection (BPC-157 territory). Whether the combination produces meaningfully different results than either alone in an oral format is exactly the research question this blend is designed to investigate.
Does both peptides survive the GI tract when taken orally?
BPC-157 has documented stability in gastric acid conditions, consistent with its origin from gastric juice. TB-500 does not have this documented stability, so its GI survival is more uncertain and dependent on capsule encapsulation providing protection. This means the two components may have different effective doses reaching intestinal tissue -- a variable that researchers should factor into study design and data interpretation when using this blend.
Why use the blend instead of separate products?
The blend simplifies protocol design for researchers who want to administer both peptides simultaneously -- one capsule instead of two separate administrations. For combination research where the interaction between the two peptides is the primary interest, co-formulation also ensures they are delivered at the same time and dose ratio in every subject. For dose-ranging experiments or protocols where individual components need independent control, separate products provide more flexibility.
Oral BPC-157 + TB-500 Blend is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
Purity99.3% avg
FormLyophilized Powder
Storage-20\u00B0C
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, TCE Worldwide for all cross-border EU and non-EU markets (UK, Switzerland, Norway, Iceland, Israel, Serbia). Delivery 1–14 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Research Library
Related Research Articles
Based on category & popularity
Researchers Also Studied
500mcgSAME FIELDOral and Capsule Research Compounds
KPV Oral Capsules 500mcg
KPV is a naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for its immunomodulatory signaling in gastrointestinal and immune biology research models. Alpha-MSH-derived immunomodulatory tripeptide Intestinal epithelial barrier and PepT1 transporter research NF-kB pathway modulation studies For research purposes only. Not for human consumption.
€309.99
500mcgSAME FIELDOral and Capsule Research Compounds
Oral TB-500 500mcg
Research-grade Oral TB-500. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Oral capsules in sealed bottle. For laboratory research use only. Not for human consumption.
€361.49
300mcgSAME FIELDOral and Capsule Research Compounds
SLU-PP-332 + BAM15 Blend 300mcg
Research-grade SLU-PP-332 + BAM15 Blend. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Oral capsules in sealed bottle. For laboratory research use only. Not for human consumption.
€154.99
500mcgSAME FIELDOral and Capsule Research Compounds
Oral BPC-157 Capsules 500mcg (60 capsules)
Enteric-coated oral BPC-157 capsules. 60 capsules per bottle, 500mcg BPC-157 per capsule (30g total per bottle). ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Supplied for in vitro research into oral peptide bioavailability and intestinal tissue protection. EU-wide 3–7 day shipping.
€137.99
Frequently researched together
Oral BPC-157 + TB-500 Blend 1000mcg€722.49
1